Club Rhumatismes et Inflammation guidelines for anti-interleukin-1 therapy: 2026 update - PubMed
4 hours ago
- #clinical guidelines
- #anti-interleukin-1 therapy
- #autoinflammatory diseases
- The 2026 update of Club Rhumatismes et Inflammation (CRI) guidelines for anti-interleukin-1 (anti-IL-1) therapy focuses on anakinra and canakinumab.
- A group of 13 experts in autoinflammatory diseases conducted a literature review up to November 2025 to develop 20 sets of guidelines.
- Guidelines cover pre-treatment assessment, patient follow-up, and management of various clinical scenarios including infections, neoplasia, cardiovascular conditions, and pregnancy.
- The guidelines serve as a practical tool for clinicians, based on the latest scientific data on efficacy and tolerance of anti-IL-1 therapy.